The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.
Called Cedars-Sinai Precision Health, the program aims to promote novel technologies and approaches for personalized medicine at the institution.
The researchers will use genomics to address challenges facing Canada's forestry, healthcare, agricultural, and aquacultural industries.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The clinical trial is designed to validate that biomarkers, measured in routine urine tests, effectively predict genetic mutations in drug-metabolizing enzymes.
The company has raised venture funding to support commercialization of a variety of blood-based cancer assays in Taiwan, but has yet to publish data validating its approach.
The company's technology will be used to analyze samples from a large cohort of Chinese volunteers to identify biomarkers for early cancer detection.
Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.
The companies will use Guardant's liquid biopsy assay to select patients with a biomarker for a clinical trial of an anti-RSP03 compound OncoMed is developing.
The company has developed a panel of 15 genes, identified from scientific literature, that specifically link to an athlete's potential to respond to power or endurance training.
The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.
The companies will collaborate to identify personalized aging-related biomarkers based on individuals' age-annotated genomic and transcriptomic data.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
The university formed the new venture in collaboration with Blueprint Bio and Emerald Logic in order to discover biomarkers for personalized medicine.
Researchers will develop PCR and next-generation sequencing assays for aberrantly methylated vimentin, with the goal of commercializing a screening test.
The NIH aims to fund projects studying the potential of exosomes and their cargo as biomarkers for cancer risk assessment, detection, diagnosis, and prognosis.
The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies.
CeMeT, short for Center for Metagenomics, was founded in 2014 as a spinout from genetic diagnostics firm CeGaT in Tübingen.
The startup will use the fund to begin commercialization of its PCR-based VerifyDx prostate cancer test.
The arrangement builds on a previous collaboration around the development and validation of the company's SeptiCyte host-response assay for sepsis diagnosis.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.